**ASX Announcement**

18 May 2023

# Withdrawal of AGM Resolutions 5(c) and 5(d)

**Melbourne**, **Australia, 18 May 2023** - Avecho Biotechnology Limited (ASX: AVE, "Avecho", or "the Company") advises that Resolutions 5(c) and 5(d) of the 2023 Notice of Annual General Meeting ("Meeting") are withdrawn from the business of the Meeting.

Resolutions 5(c) and 5(d) are being withdrawn as the 75,000,000 JLM Options ("JLM Options") to each of the Joint Lead Managers, being CoPeak Corporate Pty Ltd and CPS Capital Group Pty Ltd (or their respective nominees), as described in the Notice of Meeting, have not yet been issued and are expected to be issued no later than 3 months after the Meeting. As a result, the Company will now seek shareholder approval to issue the JLM Options under Resolutions 5(a) and 5(b) of the Notice of Meeting.

The Meeting will be held on Tuesday, 23 May 2023 at 1.00pm (AEST) at Level 22, Collins Square, Tower 5, 727 Collins Street, Melbourne, VIC 3008.

**For enquiries, please contact**
Ms Melanie Leydin
Company Secretary
+61 3 9002 5000

This announcement has been authorised by the Board of Directors of Avecho Biotechnology Limited.

**About Avecho**
Avecho Biotechnology Limited (ASX: AVE) develops and commercialises innovative Human and Animal Health products using its proprietary drug delivery system called TPM® (Tocopherol Phosphate Mixture). TPM® is derived from Vitamin E using unique, proprietary and patented processes and is proven to enhance the solubility and oral, dermal and transdermal absorption of drugs and nutrients.

Avecho's major projects include delivering TPM® enhanced injectable, oral and topical products for the human health market, including the recently announced application of TPM® to cannabinoids. The Company is also developing TPM® to enhance feed efficiency and health of livestock.

See more here - avecho.com.au